FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine. Disclosed are: use of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid or a salt thereof for preparing a medicament for treating gastoparesis in an animal subject, including a mammalian subject, wherein said gastroparesis is caused by at least one condition selected from a group consisting of diabetes, postviral syndromes, anorexia nervosa, gastric or vagus nerve surgery, amyloidosis, scleroderma, migraine with nausea and vomiting, Parkinson's disease, hypothyroidism, multiple sclerosis, as well as a condition caused by drugs, including anticholinergic agents, calcium channel blockers, opioids, antidepressants, or said gastroparesis is a symptom of any of the above conditions and a corresponding method of treatment.
EFFECT: technical result: effective stimulation of gastric emptying in clinical environment and on a model of clonidine-induced gastroparesis in dogs.
3 cl, 1 dwg, 1 tbl, 3 ex
